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Abstract The presence of atrial fibrillation (AF), the
most common sustained cardiac arrhythmia, significantly
increases the risk for stroke. Current guidelines recommend
that the vitamin K antagonist warfarin or direct oral anti-
coagulants (DOACs), such as the approved direct thrombin
inhibitor dabigatran and the approved direct factor Xa
inhibitors apixaban, rivaroxaban, and edoxaban, should be
used for thromboprophylaxis in patients with nonvalvular
AF at risk for stroke or systemic embolic events (SEE).
Warfarin, the mainstay of stroke prevention in AF,
increases the risk of major bleeding. Furthermore, warfarin
therapy comes with several limitations including frequent
monitoring and the need for dose adjustments, unpre-
dictable pharmacokinetics and pharmacodynamics, and the
potential for significant drug-drug and food-drug interac-
tions. The DOACs were developed to overcome these
limitations while maintaining or surpassing warfarin’s
efficacy and safety profiles. All four DOACs have similar
or better efficacy and safety compared with warfarin and
are therefore valuable alternatives for the prevention of
stroke and SEE in patients with nonvalvular AF. Under-
standing the subtle differences in the DOACs’ pharma-
cology, phase 3 study designs, and trial outcomes will
allow for a more tailored approach in selecting the right
oral anticoagulant for each patient.
Key Points
Direct oral anticoagulants (DOACs) offer an
attractive alternative to traditional vitamin K
antagonists for reduction in the risk of stroke in
patients with nonvalvular atrial fibrillation (AF).
The DOACs provided similar or better clinical
outcomes compared with vitamin K antagonists in
large, randomized, phase 3 trials.
There are a number of clinical issues that should be
considered when evaluating clinical trials that
evaluated DOACs in patients with AF. The
difference in each trial design makes a comparison of
these agents difficult.
1 Introduction
Atrial fibrillation (AF) is the most common sustained car-
diac arrhythmia in older adults [1, 2]. AF is independently
associated with an approximate 5-fold increase in a
patient’s stroke risk [3], with the risk of stroke attributable
to AF increasing with age [4]. Compared with those
without AF, the relative risk (RR) of stroke has been cal-
culated as 4.0-, 2.6-, 3.3-, and 4.5-fold more likely for
patients aged 50–59, 60–69, 70–79, and 80–89, respec-
tively [5]. In addition, the presence of AF at stroke onset is
associated with increased mortality and recurrence rates
[6]. Thirty-day and 1-year mortality rates in patients pre-
senting with AF at stroke onset were 32.5 and 49.5 %,
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respectively, compared with 16.2 and 27.1 % for patients
without AF at stroke onset [6]. Moreover, recurrence rates
within the first year of follow-up were higher for patients
who presented with AF at the time of stroke onset (6.6 vs.
4.4 %; p = 0.046) [6]. As such, thromboprophylaxis is a
common, though often underused [7], component to the
overall management of patients with AF.
Recent guidelines for the management of nonvalvular
AF recommend that warfarin or direct-acting oral antico-
agulants (DOACs) be used for the prevention of stroke and
systemic embolic events (SEE) in patients at risk for such
events [8, 9]. The antithrombotic agent should be selected
for the individual patient based on risk factors, cost, tol-
erability, patient preference, potential for drug interactions,
and other clinical characteristics. The approved DOACs
include the direct thrombin inhibitor dabigatran and the
direct factor Xa inhibitors rivaroxaban, apixaban, and
edoxaban [10–13]. This review will discuss the study
designs, safety, efficacy, and relevance to clinical practice
of anticoagulant options for prevention of stroke in patients
with nonvalvular AF, including traditional therapy with
warfarin and the DOACs dabigatran, rivaroxaban, apixa-
ban, and edoxaban.
2 Warfarin Therapy
The vitamin K antagonist (VKA) warfarin has been used in
clinical practice for many years and has well-established
efficacy. Warfarin, dose-adjusted to an international nor-
malized ratio (INR) of 2.0 to 3.0, reduces the risk of stroke
in patients with AF by 64 % [95 % confidence interval (CI)
49–74 %] compared with placebo/no treatment and by
39 % (95 % CI 22–52 %) compared with antiplatelet
therapy [14]. Despite its long history of use and proven
efficacy, warfarin is associated with inherent limitations
such as unpredictable pharmacokinetics (PK) and phar-
macodynamics (PD) as well as the potential for significant
drug–drug and drug–food interactions [15]. Therefore,
patients undergoing warfarin therapy require frequent
physician visits for INR monitoring and dose adjustments
to maintain a therapeutic level of anticoagulation and
reduce the risk of bleeding. In a post hoc analysis of a
randomized trial comparing warfarin therapy with anti-
platelet therapy in patients with AF, the time in the ther-
apeutic INR range (TTR) varied extensively between the
526 centers analyzed from 15 countries [16]. For patients
on warfarin therapy, at centers below the median TTR of
65 %, there was no decrease in vascular events compared
with dual antiplatelet therapy (RR, 0.93; 95 % CI
0.70–1.24, p = 0.61) [16]. However, patients receiving
oral anticoagulant therapy at centers with a TTR above
65 % showed a decrease in vascular events (RR, 2.14;
95 % CI 1.61–2.85; p\ 0.0001). In a meta-analysis of
eight randomized controlled trials in which warfarin was
used for stroke prevention in patients with AF, the INR
remained in the therapeutic range only 55–68 % of the time
[17]. Major bleeding rates varied across studies and per
year, ranging from 1.40 to 3.40 %, but typically decreased
with an increased TTR [17]. Thus, suboptimal INR control
can lead to either increased risk of thromboembolic events
or increased risk of bleeding.
Bleeding episodes can be a serious and costly conse-
quence associated with warfarin therapy. In an analysis of
medical and pharmacy claims from 47,437 patients, 0.4 % of
patients had an intracranial hemorrhage, 1.9 % had a major
gastrointestinal bleed, and 3.8 % of patients experienced a
minor gastrointestinal bleed within 30 days of a warfarin
claim [18]. Mean (standard deviation) unadjusted all-cause
healthcare costs were increased in patients with at least one
intracranial hemorrhage [US$41,903 (US$56,654)], or major
gastrointestinal bleed [US$40,586 (US$65,164)] compared
with patients with minor gastrointestinal bleed [US$24,347
(US$56,488)] or no bleeding events [US$24,129
(US$36,425)] [18]. Additional costs associated with warfarin
therapy can be the result of medication errors that lead to
adverse drug reactions [19]. In the ORBIT-AF (Outcomes
Registry for Better Informed Treatment of Atrial Fibrillation)
Registry, prior bleed (31.1 vs. 16.7, p\ 0.0001), high
bleeding risk (20.3 vs. 10.3, p\ 0.0001), and frequent falls
or frailty (20.7 vs. 7.4, p\ 0.0001) were more frequently
listed as contraindications to receiving anticoagulant therapy
in patients with a CHADS2 score C2 compared with patients
with a CHADS2 score\2 [20], despite the greater risk of
stroke attributed to these patients. Thus, there has been
interest in developing alternative agents that are easier to
manage while providing reduced risk for bleeding and fewer
drug and food interactions compared with warfarin therapy.
3 Direct Oral Anticoagulants Phase 3 Studies
Dabigatran, rivaroxaban, apixaban, and edoxaban have all
demonstrated safety and efficacy compared with warfarin
in large, randomized clinical trials for the reduction of risk
of stroke and SEE in patients with nonvalvular AF [21]. All
patients included in these trials were at an increased risk of
stroke due to one or more risk factors, such as previous
stroke or transient ischemic attack (TIA), heart failure,
diabetes mellitus, hypertension, or age C75 years.
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3.1 Study Design
The clinical trial designs for the studies are summarized in
Table 1. All four trials were noninferiority studies. In RE-
LY (Randomized Evaluation of Long Term Anticoagulant
Therapy with Dabigatran etexilate), patients were ran-
domized to either fixed doses of dabigatran, administered
in a blinded fashion, or dose-adjusted warfarin, which was
administered open-label [22]. The other three trials used a
double-blind, double-dummy design [23–25]. The
ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial Fibril-
lation) and ARISTOTLE (Apixaban for the Prevention of
Stroke in Subjects With Atrial Fibrillation) trials tested a
single dose compared with warfarin, while RE-LY and
ENGAGE AF-TIMI 48 (Effective Anticoagulation with
Factor Xa Next Generation in Atrial Fibrillation-Throm-
bolysis in Myocardial Infarction 48) trials evaluated two
different doses. A twice-daily dosing regimen was used in
RE-LY and ARISTOTLE, while ROCKET AF and
ENGAGE AF had once-daily dosing. Finally, decreased
doses of drug were included in three of the trials. In
ARISTOTLE, a decreased dose of apixaban (2.5 mg twice
daily) was used in a subset of patients with two or more of
the following characteristics: age C80 years, body weight
B60 kg, or a serum creatinine level of C1.5 mg/dL [23]. A
reduced dose of rivaroxaban (15 mg once daily) was
used in patients with a creatinine clearance (CrCl) of
30–49 mL/min in ROCKET AF [23]. In ENGAGE AF,
patients randomized to either the lower-dose regimen
(30 mg edoxaban once daily) or higher-dose regimen
(60 mg edoxaban once daily) who had an anticipated
increased drug exposure due to a CrCl of 30–50 mL/min,
body weight B60 kg, or concomitant administration of the
strong p-glycoprotein (P-gp) inhibitors verapamil, quini-
dine, or dronedarone also received a 50 % reduced dose
[26]. In addition, the 50 % dose reduction could occur at
any time during the ENGAGE AF trial if any of the above-
mentioned three criteria were met [26].
The trials had many similar inclusion criteria, requiring
the presence of AF documented by electrocardiography

































Stroke or systemic embolism
(ITT)
Stroke or systemic embolism
(mITT)
Dosage Dabigatran 110 mg or 150 mg
BID, or warfarin dose-adjusted




adjusted to a target
INR of 2.0–3.0
Apixaban 5 mg BID or
warfarin dose-adjusted to a
target INR of 2.0–3.0
Edoxaban 30 mg or 60 mg once
daily, or warfarin dose-




None 15 mg once daily for
patients with a
CrCl of 30–49 mL/
min
2.5 mg BID in a subset of
patients with 2 or more of the
following criteria: age C80,
body weight B60 kg, or serum
creatinine C1.5 mg/dL
50 % dose reduction was given
to patients with CrCl
30–50 mL/min, body weight






INR measured at least monthly;
14 days after randomization,
at 1 and 3 months, every
3 months thereafter in the first
year, and then every 4 months
until the study ended
1, 2, and 4 weeks and
monthly thereafter
Monthly for INR monitoring;
assessment every 3 months;
30 days after last dose
INR measured monthly; study
visits on days 8, 15, 29, and 60,
at month 3, and at least every
3 months thereafter
BID twice daily, CrCl creatinine clearance, DOAC direct oral anticoagulant, INR international normalized ratio, ITT intention to treat population,
mITT modified intention to treat, PP per protocol, as-treated population during treatment
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(ECG) (Table 2). However, there are some important dif-
ferences in the populations enrolled, resulting in differ-
ences in risk across trials. The RE-LY and ARISTOTLE
trials included patients with a left ventricular ejection
fraction of\40 and B40 %, respectively, values that are
consistent with a diagnosis of heart failure [22, 23].
However, ROCKET AF included patients with a left-
ventricular ejection fraction of B35 %, indicative of a
greater risk of cardiac dysfunction [24]. ROCKET AF and
ENGAGE AF recruited patients at higher risk for stroke
than RE-LY or ARISTOTLE [22–25]. The presence of AF
must have been documented within 30 days before ran-
domization in ROCKET AF, at screening or within
6 months before randomization in RE-LY, and 12 months
prior to enrollment in ARISTOTLE and ENGAGE AF [22–
25]. Patients with atrial flutter were also included in
ARISTOTLE [23].
Exclusion criteria were generally similar across all trials
(Table 3). Patients were ineligible if they had experienced
a recent stroke (within 14 days in RE-LY or ROCKET AF;
7 days in ARISTOTLE; 30 days in ENGAGE AF) [22–
25]. All trials excluded patients with severe renal dys-
function (CrCl\30 mL/min), except ARISTOTLE, which
excluded patients with CrCl\25 mL/min or a serum cre-
atinine [2.5 mg/dL [23]. Bleeding risk exclusions for
recent trauma or major surgery, gastrointestinal bleeding,
hemorrhagic disorders, and intracranial bleeding were well
defined in RE-LY, ROCKET AF, and ENGAGE AF [22,
24, 25]. In ARISTOTLE, patients with a bleeding risk
believed to be a contraindication to oral anticoagulation
were excluded [23]. Patients were allowed B100 mg daily
aspirin in the RE-LY, ROCKET AF, and ENGAGE AF
trials [22, 24, 25], and \165 mg daily aspirin in the
ARISTOTLE trial [23].











Nonvalvular AF Nonvalvular AF Nonvalvular AF or atrial





12-lead ECG, rhythm strip,
pacemaker/ICD ECG, or
Holter ECG; the duration of
AF should be C30 s. ECG
(not marker channels or
mode switch episodes) from
pacemakers and defibrillators
can be used to document only
1 episode of paroxysmal or
persistent AF
12-lead ECG, rhythm strip,
Holter, or pacemaker
interrogation and have
medical evidence of AF
before the qualifying ECG
evidence
ECG, or as an episode lasting
at least 1 min on a rhythm
strip, Holter recording, or
















persistent AF on 2 separate
occasions, at least 1 day
apart, one of which is within
6 months before
randomization
Within 30 days before
randomization and medical
evidence within 1 year
before and at least 1 day
before the ECG
On the day of screening; or on
2 separate occasions at least
2 weeks apart in the
12 months prior to
enrollment
Within the prior 12 months
Stroke risk
factors
CHADS2 index score C1
a; or
age C65 years and 1 of the
following: diabetes mellitus
on treatment; or documented
coronary artery disease; or
hypertension requiring
medical treatment
CHADS2 index score C2 CHADS2 index score C1 CHADS2 index score C2
Age C18 years C18 years C18 years C21 years
AF atrial fibrillation, DOAC direct oral anticoagulant, ECG electrocardiogram, ICD implantable cardioverter defibrillator
a Patients with only diabetes mellitus or hypertension must be C65 years of age
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Stroke Severe, disabling stroke
within the previous 6
months
Severe, disabling stroke
within 3 months; TIA
within 3 days before the
randomization visit
Ischemic stroke within 7
days
Stroke, acute MI, acute
coronary syndrome, or
percutaneous intervention
within the previous 30 days
Or any stroke within 14 days before the randomization
visit
Oral anticoagulation Indication for anticoagulant therapy for a condition other than atrial fibrillation
Contraindications Contraindication to warfarin Contraindication to
anticoagulant agents
Life expectancy \Expected duration of
the trial
\2 years B1 year \1 year
Cardiac-related
conditions
History of heart valve disorder; transient atrial fibrillation caused by a reversible
disorder (e.g., thyrotoxicosis, PE, recent surgery, MI); active endocarditis
History of heart valve
disorder (with the
exception of bioprosthetic
heart valve or valve
repair); transient atrial










Any planned Chronic anticoagulation
therapy will be
discontinued if a planned
pharmacologic, electrical,
or surgical therapy were to












[170 mmHg or diastolic
blood pressure
[100 mmHg
Bleeding risk History of or condition associated with increased
bleeding risk
Bleeding risk that is a
contraindication to oral
anticoagulation
History of or condition
associated with increased
bleeding riskActive internal bleeding
Planned surgery or
intervention
Within the next 3
months





Within 30 days before
randomization




Any history Any history Not defined Any history





disease in the previous
30 days
Within 6 months before
randomization
Not defined Within the previous year
Hemorrhagic disorder Any history Chronic Not defined Any history
Concurrent aspirin
excluded
[100 mg daily [100 mg daily [165 mg daily [100 mg daily
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All four studies assessed the efficacy and safety of the
DOACs for stroke prevention in patients with nonvalvular
AF, which was defined as AF in the absence of rheumatic
mitral stenosis, a mechanical or bioprosthetic heart valve,
or mitral valve repair [8]. It should be noted that mild
mitral stenosis was not excluded in ENGAGE AF or
ARISTOTLE, and subjects with AF and valvular heart
diseases such as mitral valve prolapse, mitral valve
regurgitation, and aortic valve disease were allowed in
ENGAGE AF [23, 25]. In ROCKET AF, hemodynamically
significant mitral valve stenosis was excluded, and hemo-
dynamically significant valvular disease was excluded in
RE-LY [22, 24].
3.2 Primary Endpoint Analyses
In all trials, the primary efficacy endpoint was noninferi-
ority compared with warfarin for stroke or SEE [22–25]. Of
note, there were differences in the analysis populations for
the primary efficacy endpoint: RE-LY and ARISTOTLE
reported noninferiority for their intent-to-treat (ITT) pop-
ulations, ROCKET AF reported for the per-protocol pop-
ulation, and ENGAGE AF analyzed the modified ITT
(mITT) population (Table 1) [22–25]; thus the ROCKET
AF and ENGAGE AF trials’ primary efficacy endpoint
analyses were performed on on-treatment patients. In
RE-LY, ARISTOTLE, and ENGAGE AF, major bleeding
was the primary safety endpoint [22–24]. All studies used
an adapted version of the International Society of Throm-
bosis and Hemostasis (ISTH) criteria for major bleeding
[22–25]. In the ROCKET AF trial, the composite of major
and clinically relevant nonmajor (CRNM) bleeding was the
primary safety endpoint [24].
4 Patient Characteristics
In ROCKET AF, more patients in the warfarin group than
patients in the rivaroxaban group had a CHADS2 score of 6
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study entry

















N/A Anticipated need for chronic
treatment with NSAIDs








































Hepatic function Active liver disease
(hepatitis A, B, or C),
ALT, AST, Alk Phos
[2x the ULN
Known significant liver
disease or ALT[3x the
ULN
ALT or AST[2x ULN
or a total bilirubin
[1.5x ULN
Active or persistent liver
disease, positive hepatitis
B or C test, ALT or AST
[2x ULN or total bilirubin
C1.5x ULN
AF atrial fibrillation, Alk Phos alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CrCl creatinine clearance,
DOAC direct oral anticoagulant, GI gastrointestinal, GP glycoprotein, IV intravenous, MI myocardial infarction, N/A not available, NSAID
nonsteroidal anti-inflammatory drug, PE pulmonary embolism, SCr serum creatinine, TIA transient ischemic attack, ULN upper limit of normal
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infarction (MI) (18.0 vs. 16.6 %, respectively) [24].
Overall, patients in ROCKET AF and ENGAGE AF were
at a greater risk of stroke than patients enrolled in other
trials, with higher CHADS2 scores overall [24, 25]. Patients
enrolled in ROCKET AF and ENGAGE AF trials also
included higher percentages of patients with diabetes,
hypertension, and congestive heart failure. More than half
the patients in ROCKET AF had a history of stroke or TIA,
with lower rates in each of the other three trials. The
proportion of patients with paroxysmal AF was higher in
RE-LY and in ENGAGE AF than in the other trials.
5 Clinical Trial Results and Approved Dosing
Recommendations
5.1 Dabigatran Etexilate
At a dose of 110 mg twice daily, dabigatran demonstrated
noninferiority to warfarin for the prevention of stroke and
SEE in patients with nonvalvular AF (p\ 0.001 for non-
inferiority; Table 5) [22]. Dabigatran 150 mg twice daily
was associated with lower rates of stroke and systemic
embolism than warfarin (p\ 0.001 for superiority) and
significantly reduced the risk for ischemic stroke (RR,
0.76; 95 % CI 0.60–0.98; p = 0.03) [21]. Both doses of
dabigatran significantly reduced the risk for hemorrhagic
stroke compared with warfarin (RR, 0.31; 95 % CI
0.17–0.56, p\ 0.001 for dabigatran 110 mg; RR, 0.26;
95 % CI 0.14–0.49; p\ 0.001 for dabigatran 150 mg).
Event rates for dabigatran were updated following publi-
cation of the primary data to reflect inclusion of events
potentially related to stroke as well as the addition of
patients who did not undergo randomization and several
deaths that occurred after the end of the study [27, 28]. The
updated event rates, which did not change the primary
conclusions of the study, are captured in Table 5.
The rate of major bleeding was similar in patients who
received warfarin or dabigatran 150 mg twice daily
(p = 0.31), and lower in patients who received dabigatran
110 mg twice daily (RR 0.80; 95 % CI 0.69–0.93,
p = 0.003 compared with warfarin; Table 6) [22]. There
was a significantly higher rate of major gastrointestinal
bleeding with dabigatran 150 mg than warfarin (RR, 1.50;









Patients (n) 18,113 14,264 18,201 21,105
Median age (years) 71 (mean) 73 70 72
Male sex (%) 64 60 65 62
Mean weight (kg) 83 28 kg/m2 (BMI) 82 (median) NR
Low body weight (%)a 2.1 28 11 10
Paroxysmal AF (%) 33 18 15 25
Persistent or permanent AF (%) 67 81b 85 75
CHADS2 score
Mean 2.1 3.5 2.1 2.8
0–1 (%) 32 0c 34 –
2 (%) 36 13 36 77 (B3)
3–6 (%) 32 87 30 23 (4–6)
Previous stroke or TIA (%) 20 55 19 28
Heart failure (%) 32 63 35 57
Diabetes mellitus (%) 23 40 25 36
Hypertension (%) 79 91 87 94
Previous VKA use (%) 50 62 57 59
Previous aspirin use (%) 40 37 31 29
Mean TTR (%) 64 55 62 65
Median TTR (%) NR 58 66 68
Median follow-up (years) 2.0 1.9 1.8 2.8
AF atrial fibrillation, NR not reported, TIA transient ischemic attack, TTR time in therapeutic range, VKA vitamin K antagonist
a For RE-LY,\50 kg; ROCKET AF, B70 kg; ARISTOTLE and ENGAGE AF-TIMI 48, B60 kg
b 1 % were newly diagnosed or new onset
c 3 patients had a score of 1
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95 % CI 1.19–1.89, p\ 0.001) [22]. The rate of intracra-
nial bleeding was significantly reduced in patients receiv-
ing dabigatran 150 mg (RR, 0.40; 95 % CI 0.27–0.60,
p\ 0.001) or dabigatran 110 mg (RR, 0.31; 95 % CI
0.20–0.47, p\ 0.001) compared with warfarin [22].
Annualized rates of other adverse events were similar
between groups, except the rate of dyspepsia was increased
with dabigatran 110 mg (11.8 %) and 150 mg (11.3 %)
compared with warfarin (5.8 %; p\ 0.001 for both com-
parisons) [22]. Updated major bleeding rates are reflected
in Table 6 [28].
Dabigatran is approved in the USA, Canada, and Europe
at an oral dose of 150 mg twice daily for patients with a
CrCl of[30 mL/min for the reduction of the risk of stroke
and SEE [11, 29, 30]. In the USA, patients with a CrCl of
15–30 mL/min should receive an oral dose of 75 mg twice
daily, and dabigatran should be avoided in patients with a
CrCl\15 mL/min or on dialysis [11]. In Canada and
Europe, a reduced dose of 110 mg is recommended for
patients with a CrCl of 30–50 mL/min [29, 30]. A reduced
dose of 75 mg twice daily may be given to patients with a
CrCl between 30 and 50 mL/min receiving dronedarone or
ketoconazole. However, dose adjustments are not neces-
sary for administration with other P-gp inhibitors [11].
Patients with a CrCl\30 mL/min who are receiving con-
comitant P-gp inhibitors should not receive dabigatran
[11]. Dabigatran should not be administered with potent
P-gp inducers [11].
5.2 Rivaroxaban
In ROCKET AF, rivaroxaban demonstrated noninferiority to
warfarin for the prevention of stroke or SEE in patients with
nonvalvular AF (p\ 0.001 for noninferiority; Table 5) [24].
Rivaroxaban demonstrated superiority in the on-treatment
analysis (p = 0.015), but not in the ITT analysis (p = 0.12),
despite the fact that there is only a difference of 28 patients
between these two analysis groups (Table 5). Rates of
hemorrhagic stroke were significantly reduced in the
rivaroxaban group compared with the warfarin group.
Major and CRNM bleeding rates were similar between
groups (p = 0.44) (Table 6) [24]. Patients in the rivarox-
aban group experienced lower rates of intracranial hem-
orrhage [hazard ratio (HR), 0.67; 95 % CI 0.47–0.93;
p = 0.02] and fatal bleeding (HR, 0.50; 95 % CI
0.31–0.79; p = 0.003) than patients in the warfarin group
[24]. It should be noted that there was more major gas-
trointestinal bleeding (3.2 vs. 2.2 %; p\ 0.001) and a
higher need for transfusion (2.6 vs. 2.15 %; p = 0.04) with
the use of rivaroxaban compared with warfarin [24]. Rates
of other adverse events were similar between groups.
The reduced dose of rivaroxaban (15 mg once daily) or
rivaroxaban placebo, for patients with moderate renal
insufficiency, was used in 21 % of patients in both groups
[24]. The primary efficacy and safety outcomes were
consistent with the outcomes demonstrated with those who
received full dose.
Table 6 Safety of DOACs compared with warfarin in phase 3 clinical trials for the prevention of stroke or systemic embolism in patients with
atrial fibrillation [22–25, 28]
Outcome (ERa) RE-LY ROCKET AF ARISTOTLE ENGAGE AF-TIMI 48
Dabigatranb Warfarin Rivaroxaban Warfarin Apixaban Warfarin Edoxaban Warfarin




Major bleeding 2.92 3.40 3.61 3.6 3.4 2.13 3.09 1.61 2.75 3.43
p = 0.003 p = 0.41 p = 0.58 p\ 0.001 p\ 0.001 p\ 0.001
Major or CRNM
bleeding
NR NR NR 14.9 14.5 4.07 6.01 7.97 11.10 13.02
p = 0.44 p\ 0.001 p\ 0.001 p\ 0.001
Intracranial
bleeding
0.23 0.30 0.74 0.5 0.7 0.33 0.80 0.26 0.39 0.85
p\ 0.001 p\ 0.001 p = 0.02 p\ 0.001 p\ 0.001 p\ 0.001
GI bleeding 1.12 1.51 1.02 3.2 2.2 0.76 0.86 0.82 1.51 1.23
p = 0.43 p\ 0.001 p\ 0.001 p = 0.37 p\ 0.001 p = 0.03
Any bleeding 14.62 16.42 18.15 NR NR 18.1 25.8 10.68 14.15 16.40
p\ 0.001 p = 0.002 p\ 0.001 p\ 0.001 p\ 0.001
CI confidence interval, CRNM clinically relevant nonmajor, DOAC direct oral anticoagulant, GI gastrointestinal, NR not reported
All p values for superiority
a Event rate for RE-LY, ARISTOTLE, and ENGAGE AF was %/year; for ROCKET AF, number/100 PY
b Data for major bleeding reflect updated values from 2014 [28]
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In patients with a CrCl[50 mL/min, rivaroxaban
should be administered with the evening meal at a dose of
20 mg once daily [12]. Patients with a CrCl of 15–50 mL/min
should receive a reduced dose of 15 mg once daily at
the evening meal [12]. Rivaroxaban should not be given
with combined P-gp and strong cytochrome P450 3A4
(CYP3A4) inhibitors or combined P-gp and strong
CYP3A4 inducers [12].
5.3 Apixaban
Apixaban demonstrated a lower annualized rate of stroke
or SEE than warfarin in patients with AF (p\ 0.001 for
noninferiority; p = 0.01 for superiority; Table 5) [23].
There was a significant reduction in risk for hemorrhagic
stroke among patients who received apixaban compared
with warfarin.
Major bleeding rates were lower in the apixaban group
compared with the warfarin group (HR, 0.69; 95 % CI
0.60–0.80, p\ 0.001) (Table 6). Similarly, major or
CRNM bleeding occurred less frequently in patients who
received apixaban than patients who received warfarin
(HR, 0.68; 95 % CI 0.61–0.75, p\ 0.001). Rates of other
adverse events were similar between groups.
The reduced dose of apixaban 2.5 mg twice daily was
administered in 4.7 % of patients in the apixaban group [23].
The primary efficacy and safety outcomes were not signifi-
cantly different for patients who received the 2.5 mg twice-
daily dose compared with those who received the full dose.
For the reduction of risk of stroke and SEE in nonva-
lvular AF, patients should receive oral apixaban 5 mg
twice daily [10]. A reduced oral dose of 2.5 mg twice daily
should be given to patients in whom at least two of the
following are true: age C80 years, body weight B60 kg, or
serum creatinine C1.5 mg/dL [10]. Patients receiving
strong dual inhibitors of CYP3A4 and P-gp should be given
a reduced dose of 2.5 mg twice daily. However, patients
already taking apixaban 2.5 mg twice daily should avoid
coadministration of apixaban with strong dual inhibitors of
CYP3A4 and P-gp [10]. Patients taking strong dual
inducers of CYP3A4 and P-gp should not receive apixaban
[10].
5.4 Edoxaban
Both the higher- (60 mg) and lower-dose (30 mg) regimens
of edoxaban demonstrated noninferiority to warfarin in
prevention of stroke or SEE in patients with AF (HR, 0.79;
97.5 % CI 0.63–0.99, p\ 0.001 and HR, 1.07; 97.5 % CI
0.87–1.31, p = 0.005, respectively; Table 5) [25]. Fur-
thermore, higher-dose edoxaban demonstrated superiority
(p = 0.02) to warfarin when the mITT population was
analyzed, but this superiority was lost when the ITT
population was tested (p = 0.08). Treatment with either
dose of edoxaban led to significantly reduced risks for
hemorrhagic stroke compared with warfarin (HR, 0.54;
95 % CI 0.38–0.77, p\ 0.001 and HR, 0.33; 95 % CI
0.22–0.50, p\ 0.001 for higher- and lower-dose edoxaban,
respectively). While the efficacy and safety evaluation of
edoxaban was stratified by varying degrees of renal func-
tion for regulatory approval [13], a published analysis in
this population is not yet available.
Annualized rates of major bleeding were decreased in
patients who received either the higher- or lower-dose
regimens of edoxaban compared with warfarin (HR, 0.80;
95 % CI 0.71–0.91, p\ 0.001; HR, 0.47; 95 % CI
0.41–0.45, p\ 0.001) for the higher and lower dose,
respectively) (Table 6) [25].
Rates of stroke or SEE in patients who received the
50 % dose reduction were 2.32 % for the higher-dose
group (30 mg), 3.14 % for the lower-dose group (15 mg),
and 2.68 % for patients with similar characteristics in the
warfarin group. The resulting HRs and corresponding 95 %
CIs were not significantly different to those for the full
dosing groups [25]. However, the resulting reductions in
the risk for major bleeding were significantly greater for
patients in the higher- and lower-dose edoxaban regimens
who received a 50 % dose reduction compared to those
who did not (p = 0.02 and p\ 0.01 for interaction,
respectively). Major bleeding rates for reduced-dose
edoxaban patients were 3.05 % for higher-dose group
(30 mg) and 1.50 % for lower-dose group (15 mg) versus
4.85 % for warfarin patients with similar characteristics
[25].
For the prevention of stroke and SEE in patients with
nonvalvular AF, edoxaban 60 mg once daily is approved in
the USA [13] and Japan [31], and is approved in other
countries, including the European Union [32]. Edoxaban
should not be used in patients with CrCl[ 95 mL/min
[13]. A reduced, once-daily dose of edoxaban 30 mg
should be used in patients with CrCl 15–50 mL/min.
Edoxaban should not be coadministered with rifampin [13].
6 Subpopulations
Patients with a history of stroke or TIA are at an increased
risk of reoccurrence [33]. The DOAC trials included
patients who had a previous stroke or TIA. There were
3623 patients (20 %) in the RE-LY trial that had a previous
stroke or TIA. Of these patients, 2.78 % per year in the
warfarin group experienced a stroke or SEE, 2.32 % per
year in the dabigatran 110 mg group (RR, 0.84; 95% CI
0.58–1.20), and 2.07 % per year in the dabigatran 150 mg
group (RR, 0.75; 95 % CI 0.52–1.08) [34]. In ROCKET
AF, 7468 patients (52 %) had a previous stroke or TIA. In
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rivaroxaban-treated patients, 2.79 events/100 PY of stroke
or SEE compared with 2.96 events/100 PY occurred in
warfarin-treated patients (HR, 0.94; 95 % CI 0.77–1.16)
[35]. Prior stroke or TIA occurred in 3436 patients (19 %)
in the ARISTOTLE trial. In these patients, stroke or SEE
rates were 2.5 % per year for apixaban-treated patients and
3.2 % per year for warfarin-treated patients [23]. In the
ENGAGE AF trial, 5973 patients (28 %) had a previous
stroke or TIA. The rate of the primary efficacy outcome
was 2.44 % per year with higher-dose edoxaban, 3.19 %
per year with lower-dose edoxaban, and 2.85 % per year
with warfarin [25]. These results identify DOACs as an
option in patients with AF and a history of stroke or TIA.
All of the DOACs are dependent on renal function for
drug clearance, with dabigatran exhibiting the greatest
renal dependence. Roughly 80 % of the absorbed dose of
dabigatran is cleared by the kidneys [11], 66 and 35 % of
orally administered doses of rivaroxaban and edoxaban,
respectively, are eliminated by kidneys [12, 13]. Apixaban
has the least renal dependence of the DOACs, with 27 % of
the oral dose cleared renally [10]. Patients with renal
dysfunction may experience impaired excretion of parent
drugs, which can result in excessive drug accumulation and
altered drug distribution and elimination [36]. Due to these
considerations, the US Food and Drug Administration
(FDA) has issued recommendations regarding the evalua-
tion of drugs in patients with renal impairment [37], and
thus, all studies included patients with moderate renal
impairment (CrCl 30–50 mL/min). In RE-LY, 3505
patients (19 %) had a CrCl of\50 mL/min. In this subset
of patients, the rate of stroke or SEE was 2.15 % per year
in patients treated with dabigatran 110 mg, 1.52 % per year
with dabigatran 150 mg, and 2.78 % per year with warfarin
[22]. Patients in the ROCKET AF trial with moderate renal
impairment (CrCl of 30–49 mL/min) received a reduced
dose of rivaroxaban (15 mg daily). Moderate renal
impairment was seen in 2950 (21 %) patients in ROCKET
AF. The rate of stroke or SEE was higher in patients with
moderate renal impairment than patients with
CrCl[ 50 mL/min (2.32 vs. 1.57 events/100 PY in
rivaroxaban-treated patients and 2.77 vs. 2.00 events/100
PY in warfarin-treated patients, respectively) [38]. In the
ARISTOTLE trial, 3017 patients had moderate or severe
renal impairment (CrCl B 50 mL/min). The rates of stroke
or SEE were 2.1 % per year in apixaban-treated patients
and 2.7 % per year in warfarin-treated patients [23]. Major
bleeding was lower in apixaban-treated patients than war-
farin-treated patients (3.2 vs. 6.4 %, respectively) [23]. As
previously described, patients in ENGAGE AF received a
50 % decreased dose of edoxaban if they had CrCl of
30–50 mL/min, along with those who had a body weight
B60 kg, or concomitant administration of strong P-gp
inhibitors [25]. Within either dosing regimen of edoxaban,
the 50 % dose reduction did not impact the efficacy of
edoxaban, while it did lead to a significantly greater risk
reduction for major bleeding compared with those who
received full dose edoxaban. For patients with a CrCl of
30–50 mL/min, the rates of stroke or SEE were similar (2.3
and 2.7 % for edoxaban 60 mg and warfarin, respectively)
[13]. Patients with a CrCl of 30–50 mL/min receiving
higher-dose edoxaban had a lower major bleeding rate
relative to warfarin (3.8 % compared with 5.1 %, respec-
tively; HR, 0.76; 95% CI 0.58–0.99) [13]. Additional post
hoc analyses stratified by renal function indicated that the
rates of ischemic stroke were increased with the use of
edoxaban relative to warfarin in nonvalvular AF patients
with CrCl[95 mL/min due to lower plasma concentrations
of edoxaban [13, 39]. Therefore, edoxaban should not be
used in patients with AF and a CrCl[ 95 mL/min.
The efficacy and safety of DOACs is similar in patients
C75 years of age compared with patients\75 years of age
[40]. The rates of stroke or SEE are reduced relative to
warfarin, and associated with a lower risk of bleeding in
phase 3 trials [22–25]. Edoxaban, rivaroxaban, and apixaban
exhibited no differences in efficacy or safety in elderly
patients compared with younger patients [23–25]. Dabiga-
tran has a significant interaction of age by treatment, with
both 110 and 150 mg of dabigatran producing a higher risk
of major bleeding in patients C75 compared with patients
\75 years of age [41]. Edoxaban decreased the absolute risk
of major bleeding, including intracranial hemorrhage, in
elderly patients compared with warfarin [42].
All trials included patients who had previously been on a
VKA as well as VKA-naı¨ve patients. In the RE-LY trial,
9123 patients were VKA-naı¨ve and 8989 patients were
VKA-experienced. The annualized rate of stroke and SEE
in VKA-naı¨ve patients was 1.57, 1.07, and 1.69 % for
dabigatran 110 mg, dabigatran 150 mg, and warfarin,
respectively (p = 0.65 for dabigatran 110 mg to warfarin;
p = 0.005 for dabigatran 150 mg to warfarin) [43]. In
VKA-experienced patients, the primary endpoint occurred
in 1.51, 1.15, and 1.74 % per year, respectively (p = 0.32
for dabigatran 110 mg to warfarin; p = 0.007 for dabiga-
tran 150 mg to warfarin). Major bleeding rates in dabiga-
tran-treated VKA-naı¨ve patients were lower (dabigatran
110 mg) or similar (dabigatran 150 mg) to warfarin [43].
In ROCKET AF, 6367 patients were VKA-naı¨ve and 7897
patients were VKA-experienced. Rates of stroke and SEE
were similar between rivaroxaban- or warfarin-treated
patients in VKA-naı¨ve (2.32 vs. 2.87 events/100 PY) and
VKA-experienced patients (1.98 vs. 2.09 events/100 PY)
[44]. During the first seven days, rivaroxaban patients
experienced more bleeding than warfarin patients in VKA-
naı¨ve and -experienced patients. However, after 30 days,
rivaroxaban was associated with less bleeding in VKA-
naı¨ve patients and similar bleeding in VKA-experienced
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patients [44]. In ARISTOTLE, 10,401 patients were VKA-
experienced while 7800 were VKA-naı¨ve. The primary
efficacy outcome occurred in 1.1 % per year of VKA-ex-
perienced patients treated with apixaban and 1.5 % per
year of VKA-experienced patients treated with warfarin
[23]. In VKA-naı¨ve patients, 1.5 % per year experienced
the primary outcome when treated with apixaban compared
with 1.8 % per year of patients treated with warfarin.
Annualized major bleeding rates were lower in patients
treated with apixaban compared with warfarin in VKA-
naı¨ve (2.2 vs. 3.0 %) and VKA-experienced patients (2.1
vs. 3.2 %) [23]. There were 8663 VKA-naı¨ve and 12,441
VKA-experienced patients in ENGAGE AF. The rates of
the primary efficacy endpoints were 1.49, 1.97, and 2.12 %
per year with higher-dose edoxaban, lower-dose edoxaban,
and warfarin, respectively, in VKA-naı¨ve patients [25]. In
VKA-experienced patients the primary efficacy endpoint
rates were 1.62, 2.08, and 1.60 % per year, respectively.
Major bleeding rates were decreased with high- and low-
dose edoxaban compared with warfarin [25]. These data
demonstrate that DOACs are effective in both VKA-naı¨ve
and -experienced patients.
In the RE-LY trial, 1270 patients underwent cardiover-
sion: 647, 672, and 664 in the dabigatran 110 mg, dabi-
gatran 150 mg, and warfarin groups, respectively. Rates of
stroke and SEE were 0.8, 0.3, and 0.6 %, respectively, at
30 days [45]. Rates of major bleeding were 1.7, 0.6, and
0.6 %, respectively. Cardioversion or AF ablation was
completed in 321 patients in ROCKET AF [46]. Rates of
stroke or SEE (1.88 vs. 1.86 %) and death (1.88 vs.
3.73 %) were similar between rivaroxaban-treated and
warfarin-treated patients, respectively [46]. In a prospec-
tive randomized trial of rivaroxaban in patients with AF
undergoing elective cardioversion, rivaroxaban was asso-
ciated with a significantly shorter time to cardioversion and
was associated with similar rates of major bleeding com-
pared to VKAs [47]. During ARISTOTLE, 743 car-
dioversions occurred in 540 patients; 265 receiving
apixaban and 275 receiving warfarin. No stroke or SEE
occurred during the 30-day follow-up in these patients.
There was one incident of MI, one of major bleeding, and
two deaths in each treatment group [48]. These results
represent a small number of patients, but demonstrate that
DOACs are a reasonable alternative to warfarin in patients
requiring cardioversion.
7 Determining Risk and Guideline
Recommendations
Stratification schemes are available to quantify the risk of
stroke in patients with AF (Table 7). The CHADS2 score
assigns 1 point each for the presence of chronic heart
failure, hypertension, age C75 years, and diabetes mellitus;
and 2 points for history of stroke or TIA [33]. For each
1-point increase in the CHADS2 score, stroke rate increases
by a factor of 1.5 (95 % CI 1.3–1.7) per 100 PY without
antithrombotic therapy [33]. Patients with no risk factors
can be managed with aspirin or no antithrombotic therapy
[33]. Patients with AF who have one definitive risk factor
or have two or more combination risk factors should be
considered for oral anticoagulation [49].
To better identify patients with AF who are at low and
moderate risk for stroke, the CHADS2 score has been
refined to incorporate additional risk factors and is now
referred to as the CHA2DS2-VASc score (Table 7) [49, 50].
As such, the CHA2DS2-VASc is now the preferred mode
for assessing stroke risk [8, 9].
Current guidelines for the management of AF from the
American Heart Association/American College of Cardi-
ology/Heart Rhythm Society (AHA/ACC/HRS) and the
European Society of Cardiology (ESC) recommend
DOACs or warfarin for prevention of thromboembolism
in nonvalvular AF patients with prior stroke, TIA, or
CHA2DS2-VASc score C2, with consideration of risk of
stroke, risk of bleeding, and patient preferences [8, 9]. No
antithrombotic therapy is recommended for patients with a
score of 0 [8, 9]. With moderate to severe chronic kidney
disease, reduced doses of DOACs may be considered,
although not in patients with end-stage chronic kidney
disease [8]. Warfarin is recommended for patients with
CrCl\ 15 mL/min or on hemodialysis who have a
CHA2DS2-VASc score C2 [8]. In addition, ESC recom-
mends that oral anticoagulation should be considered in
patients with scores as low as 1, upon assessment of the
risk of bleeding complications and patient preferences. The
ESC recommends one of the DOACs rather than a dose-
adjusted VKA for most patients when oral anticoagulation
is recommended [9]. The AHA/ACC/HRS recommends
DOACs over warfarin only for patients who are unable to
maintain a therapeutic INR [8].
Stroke risk is also closely linked to bleeding risk. The
use of the HAS-BLED score improves the predictive
accuracy of bleeding risk and can be used in conjunction
with stroke risk scores to determine if anticoagulant ther-
apy should be initiated in patients with AF who are not
undergoing antithrombotic therapy or if antiplatelet therapy
is under consideration [51]. A score C3 indicates a patient
who is potentially at high risk for bleeding events [51].
HAS-BLED demonstrates good predictive accuracy over-
all, with a better predictive accuracy for patients receiving
either no antithrombotic therapy or antiplatelet therapy
[51]. The ESC recommends the use of the HAS-BLED
bleeding risk stratification scheme in conjunction with the
use of CHA2DS2-VASc [9]. However, it should be noted
that there is limited validation for the use of HAS-BLED.
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Further, bleeding risk should not be used as a reason to
exclude or discontinue anticoagulation [52], and patients at
a high risk for stroke rarely have a bleeding risk exceeding
their risk of stroke [53, 54].
8 Discussion
A superficial review of these trial results may convince
clinicians that there are differences between the results of
these agents for certain endpoints that were evaluated.
While this may be a tempting conclusion, it is critical that
clinicians understand that differences in the study designs
and study populations make this extremely difficult.
The trials used different populations of patients in the
statistical determination of noninferiority to warfarin in
their primary endpoints (i.e. ITT, mITT, or per protocol).
In an ITT design, the randomized subjects are analyzed in
the groups to which they were assigned regardless of
whether they received or adhered to their treatment. In
ENGAGE-AF, the treatment period was the period
between administration of the first dose of the study drug
and either three days after the receipt of the last dose or the
end of the double-blind therapy. Events were censored
during study-drug interruptions that lasted more than
three days. In the ROCKET AF study ‘‘per-protocol’’
‘‘on-treatment,’’ only subjects who fulfilled the protocol in
terms of the eligibility, interventions, and outcome
assessment were analyzed. This restricts the treatment
comparisons to the ideal patients who adhered perfectly to
the protocol stipulations. For the practicing clinician,
evaluating patient adherence and the likelihood of therapy
interruptions may be an important consideration in drug
selection and anticipated outcomes.
Use of ITT versus on-treatment populations for non-
inferiority studies is controversial [55] and the FDA rec-
ommends that results for noninferiority analyses be
reported for both populations [56]. The inclusion of all
patients randomized to treatment in the ITT population
avoids biases associated with switching treatment, dropout
patterns, or patient selection. However, these analyses also
include patient outcomes that occur after patients have
ceased treatment, and include patients with poor adherence.
However, exclusion of patients who have dropped out of a
study, in the on-treatment population, can introduce bias
toward noninferiority. Thus, when the results are robust for
both populations in a study, noninferiority is firmly estab-
lished [55, 56]. Alternately, discrepancies between the ITT
Table 7 Risk stratification scoring schema [8, 51]
CHADS2 CHA2DS2-VASc
Clinical Characteristic Points awarded Clinical characteristic Points awarded
Congestive heart failure 1 Congestive heart failure 1
Hypertension 1 Hypertension 1
Age[75 years 1 Age[75 years 2
Diabetes mellitus 1 Diabetes mellitus 1
Prior stroke/TIA/Thromboembolism 2 Prior stroke/TIA/thromboembolism 2
Maximum score 6 Vascular disease (prior MI, PAD, aortic plaque) 1
Age 65–75 years 1
Sex category (female) 1
Maximum score 9
HAS-BLED
Clinical characteristic Points awarded
Hypertension 1





Drugs or alcohol (1 point each) 1 or 2
Maximum score 9
INR international normalized ratio, MI myocardial infarction, PAD peripheral artery disease, TIA transient ischemic attack
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and on-treatment noninferiority analyses can suggest an
inclusion bias and that exclusion of patients from the on-
treatment population was treatment-related [55]. Only the
ROCKET AF trial reported noninferiority for both on-
treatment and ITT populations; p\ 0.001 for both
(Table 5).
While each of these agents has demonstrated an
impressive outcome that may seem to separate it from the
pack, there are also concerns that challenge this potential
advantage. Dabigatran and apixaban were the only two
agents to demonstrate superiority in the ITT analysis, and
rivaroxaban and edoxaban did so only in the per-protocol
and mITT analyses, respectively. These results may be
suggestive that dabigatran and apixaban are more effective
agents for the prevention of stroke and SEE in patients with
nonvalvular AF. While this could be true, there are other
factors that should be considered (Table 4). It is important
to note that in the RE-LY and ARISTOTLE trials, the
mean CHADS2 score was only 2.2 and 2.1, respectively.
By comparison, patients in the ROCKET AF and
ENGAGE AF trials had a higher risk of stroke with mean
CHADS2 score of 3.5 and 2.8, respectively. Patients with a
CHADS2 score of 0 or 1, who may not even need antico-
agulant therapy, made up about one-third of the total
patients in RE-LY and ARISTOTLE, and only three
patients in ROCKET AF had this level of low risk. In
comparison, about one-third of patients in RE-LY and
ARISTOTLE were high-risk, with a CHADS2 score of C3.
The ROCKET AF trial had 87 % of patients in this high-
risk group. Patients in RE-LY and ARISTOTLE consis-
tently had lower incidence of all components of the
CHADS2 score compared with patients in ROCKET AF
and ENGAGE AF (Table 4). Therefore, differences in
patient populations studied are important to consider when
evaluating these results.
In addition to differences in the patient populations
studied, a recent reinterpretation of the DOAC phase 3 trial
results suggest that the failure of rivaroxaban and higher-
dose regimen edoxaban to demonstrate superiority over
warfarin in their ITT analyses of the primary efficacy
endpoint may be due to an imbalance of off-treatment
events in the DOAC arms compared with the warfarin
arms. These high discontinuation rates, coupled with more
off-treatment events, would dilute the benefits of the
treatment effect in the ITT analyses [57].
While all of the DOACs provided a significant reduction
in hemorrhagic stroke in the trials, only dabigatran pro-
vided a significant reduction in the rates of ischemic stroke
compared with warfarin (Table 5). In RE-LY, warfarin was
administered in an open-label manner and INR was mon-
itored and adjusted locally. In the other three trials, due to
their double-blind, double-dummy designs, INR monitor-
ing was done through standardized, encrypted, point-of-
care devices that provide INR reading (real or sham) to the
site investigators. This difference may result in greater
variability in warfarin control at the individual patient level
when warfarin is administered open-label compared with
blinded, as demonstrated in an analysis of the SPORTIF
(Stroke Prevention Using Thrombin Inhibitor in Atrial
Fibrillation) III (open-label) and V (blinded) trials [58].
While the rate of stroke and SEE was 1.2 % for ximela-
gatran in both studies, the efficacy outcome occurred in
2.3 % of patients receiving open-label warfarin in the
SPORTIF III trial, but improved to 1.2 % with blinded
warfarin in the SPORTIF V trial. Therefore, open-label
warfarin resulted in a stroke and SEE rate that was almost
twice that of blinded warfarin [58]. Thus, it may be that in
RE-LY there was greater individual INR variability that
contributed to the higher ischemic stroke rate observed in
the warfarin treatment group. It should also be noted that in
more recent trials, such as RE-LY, warfarin management
was dictated by a nomogram or algorithm [22]. Therefore,
fluctuations in outcomes in warfarin therapy may be less
dramatic as in the older SPORTIF trials. This may explain
why the TTR was lower in the ROCKET AF trial than the
other DOAC trials. While investigators in the RE-LY,
ARISTOTLE, and ENGAGE AF trials were provided
guidance on warfarin management, investigators in the
ROCKET AF trial were not and managed warfarin
according to their usual practice [22–25].
The ROCKET AF patient population had the highest
risk of stroke compared to the other trials, but the efficacy
of rivaroxaban was not superior to warfarin based on the
ITT analysis. Apixaban, with patients at lower risk for
stroke (based on mean CHADS2 score) demonstrated
superior efficacy over warfarin in its ITT analysis. How-
ever, the absolute differences in event rates in ROCKET
AF and ARISTOTLE are the same. The trials also calcu-
lated the important outcome of major bleeding over dif-
ferent periods of time. Both apixaban and either dose of
edoxaban significantly reduced major bleeding rates com-
pared with warfarin, whereas rivaroxaban and dabigatran
demonstrated similar rates of major bleeding compared
with warfarin. While this may be due to truly better safety
with apixaban and edoxaban, it may also be due to how
bleeding events were accrued. In the ARISTOTLE and
ENGAGE AF trials, bleeding events were only included if
they occurred 2 or 3 days, respectively, after last dose. In
the RE-LY and ROCKET AF trials, bleeding events were
recorded over the duration of the study for both dabigatran
and rivaroxaban.
Based on the differences discussed here, it seems diffi-
cult to suggest that one agent has a defined benefit over
another in patients with nonvalvular AF. Therefore, a
collective review of these data as a class of agents may be
most appropriate. A meta-analysis of all 71,683
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participants in the RE-LY, ROCKET AF, ARISTOTLE,
and ENGAGE AF trials compared DOACs to warfarin
[40]. Stroke or SEE were reduced by 19 % by DOACs
compared with warfarin (RR, 0.81; 95 % CI 0.73–0.91;
p\ 0.0001). DOACs significantly reduced all-cause mor-
tality (RR, 0.90; 95 % CI 0.85–0.95; p = 0.0003) and
intracranial hemorrhage (RR, 0.48; 95 % CI 0.39–0.59;
p\ 0.0001), but increased gastrointestinal bleeding (RR,
1.25; 95 % CI 1.01–1.55; p = 0.04) [40]. Finally, in an
analysis of the net clinical benefit of the DOACs compared
with warfarin based on the phase 3 clinical trials, each
DOAC evaluated had a favorable net clinical benefit in
comparison with warfarin [59]. All four DOACs had sig-
nificant net clinical benefit for the composite of disabling
stroke plus life-threatening bleeding [59].
As clinicians decide on the optimal DOAC for reducing
the risk of stroke in a patient with AF, patient adherence
should be considered. It is unlikely that patients who are
nonadherent to warfarin therapy would be adherent with a
DOAC, although DOACs may be advantageous in patients
where nonadherence results or occurs because of frequent
warfarin monitoring requirements. Another issue to con-
sider in adherence is dosing frequency. In a study of 103
anticoagulation clinic patients, 11 patients were found to be
nonadherent within 3 months of initiation of twice-daily
dabigatran. Adherence was defined as taking [80 % of
required doses [60]. There were also 30 % of patients who
reported missing doses during this time frame, with one
reporting missing a dose every day [60]. An additional
study of 5376 Veterans Affairs’ patients evaluated adher-
ence of twice-daily dabigatran and found a connection to
outcomes. Using the same definition of adherence as the
previous study, 28 % of patients were found to be nonad-
herent to dabigatran therapy. The investigators determined
that for every 10 % decrease in adherence there was an
associated 13 % increased risk of stroke and all-cause
mortality [61]. Therefore, once-daily DOAC therapy may
be preferred to twice-daily therapy in patients in whom
adherence with a more complex regimen might be a con-
cern. While there are no comparable data to show that
adherence with once-daily is better than twice-daily DOAC
therapy, adherence with once-daily cardiovascular medi-
cations are typically better than twice-daily medications
[62]. Data on DOAC persistence are limited. Registry data
suggest that rivaroxaban persistence was greater than VKA
persistence, with few discontinuations due to thromboem-
bolic complications, although bleeding was the most fre-
quent reason for discontinuation [63]. In the same registry,
rates of discontinuation of dabigatran were comparable to
rates for VKA, and dabigatran discontinuation was pri-
marily due to gastrointestinal side effects [64].
Limited post-marketing data are available for dabiga-
tran. A comparison of bleeding rates for dabigatran and
warfarin using insurance-claim data and administrative
data from the FDA Mini-Sentinel database demonstrated
similar bleeding rates for these medications from October
19, 2010 (dabigatran approval date), to December 31, 2011
[65]. In patients with AF, the incidence of gastrointestinal
hemorrhage in patients who received dabigatran was 1.6
per 100,000 days at risk compared with 3.5 per
100,000 days at risk in patients who received warfarin.
Similarly, the intracranial hemorrhage rate was 0.8 per
100,000 days at risk in patients who received dabigatran
and 2.4 per 100,000 days at risk in patients who received
warfarin [65]. To date, the dabigatran post-marketing data
mirror trial results [66].
Post-marketing data are also available for rivaroxaban
from the Department of Defense electronic medical record
[67]. Data were collected from January 1, 2013, to March
31, 2014, in 27,467 patients with nonvalvular AF to eval-
uate major bleeding. The incidence of major bleeding in
these patients was 2.9 per 100 PY, which is similar to the
3.6 per 100 PY demonstrated in the ROCKET AF trial. Use
of rivaroxaban in a ‘‘real world’’ setting does not seem to
be associated with an increased risk of major bleeding.
In a recent literature review, 26 published cases of
severe hemorrhagic complications with dabigatran and two
such cases for rivaroxaban were presented [68]. Cases were
assessed for three risk factors of hemorrhagic complica-
tions: (1) prescriber error; (2) renal impairment; or (3) age
[80 years with body weight\60 kg. At least one of these
three risk factors was present in 78 % of cases [68]. This
suggests that clinicians must make informed choices in
determining the appropriate DOAC for each patient. In
summary, the introduction of DOACs, while simplifying
treatment, may generate additional controversy because
DOAC trials were different enough from each other that
direct comparison among them is not possible.
9 Conclusion
The DOACs provide further options for patients with non-
valvular AF at risk for stroke in addition to traditional
therapy with warfarin. The clinician has several individual
patient factors to consider including risk factors, tolerability,
patient preference, potential for drug interaction, and other
clinical characteristics. The DOACs have demonstrated
efficacy and safety that are similar to or better than warfarin
in large, randomized clinical trials and are valuable alter-
natives to warfarin in patients with nonvalvular AF.
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